Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- PMID: 32534646
- DOI: 10.1016/S0140-6736(20)30934-X
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Erratum in
-
Department of Error.Lancet. 2020 Aug 15;396(10249):466. doi: 10.1016/S0140-6736(20)31721-9. Lancet. 2020. PMID: 32798490 No abstract available.
Abstract
Background: IMspire150 aimed to evaluate first-line combination treatment with BRAF plus MEK inhibitors and immune checkpoint therapy in BRAFV600 mutation-positive advanced or metastatic melanoma.
Methods: IMspire150 was a randomised, double-blind, placebo-controlled phase 3 study done at 112 institutes in 20 countries. Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned 1:1 to 28-day cycles of atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) or atezolizumab placebo, vemurafenib, and cobimetinib (control group). In cycle 1, all patients received vemurafenib and cobimetinib only; atezolizumab placebo was added from cycle 2 onward. Randomisation was stratified by lactate dehydrogenase concentration and geographical region. Blinding for atezolizumab was achieved by means of an identical intravenous placebo, and blinding for vemurafenib was achieved by means of a placebo tablet. The primary outcome was investigator-assessed progression-free survival. This trial (ClinicalTrials.gov, NCT02908672) is ongoing but no longer recruiting patients.
Findings: Between Jan 13, 2017, and April 26, 2018, 777 patients were screened and 514 were enrolled and randomly assigned to the atezolizumab group (n=256) or control group (n=258). At a median follow-up of 18·9 months (IQR 10·4-23·8), progression-free survival as assessed by the study investigator was significantly prolonged with atezolizumab versus control (15·1 vs 10·6 months; hazard ratio [HR] 0·78; 95% CI 0·63-0·97; p=0·025). Common treatment-related adverse events (>30%) in the atezolizumab and control groups were blood creatinine phosphokinase increased (51·3% vs 44·8%), diarrhoea (42·2% vs 46·6%), rash (40·9%, both groups), arthralgia (39·1% vs 28·1%), pyrexia (38·7% vs 26·0%), alanine aminotransferase increased (33·9% vs 22·8%), and lipase increased (32·2% vs 27·4%); 13% of patients in the atezolizumab group and 16% in the control group stopped all treatment because of adverse events.
Interpretation: The addition of atezolizumab to targeted therapy with vemurafenib and cobimetinib was safe and tolerable and significantly increased progression-free survival in patients with BRAFV600 mutation-positive advanced melanoma.
Funding: F Hoffmann-La Roche and Genentech.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Comment in
-
Triple therapy for BRAFV600-mutated melanoma.Lancet. 2020 Jun 13;395(10240):1814-1815. doi: 10.1016/S0140-6736(20)31285-X. Lancet. 2020. PMID: 32534635 Free PMC article. No abstract available.
Similar articles
-
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.Lancet Oncol. 2023 Jan;24(1):33-44. doi: 10.1016/S1470-2045(22)00687-8. Epub 2022 Nov 29. Lancet Oncol. 2023. PMID: 36460017 Clinical Trial.
-
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.Lancet Oncol. 2016 Sep;17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X. Epub 2016 Jul 30. Lancet Oncol. 2016. PMID: 27480103 Clinical Trial.
-
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.Lancet Oncol. 2022 Sep;23(9):1145-1155. doi: 10.1016/S1470-2045(22)00452-1. Epub 2022 Aug 5. Lancet Oncol. 2022. Retraction in: Lancet Oncol. 2023 Aug;24(8):832. doi: 10.1016/S1470-2045(23)00327-3. Retracted and republished in: Lancet Oncol. 2023 Aug;24(8):e327. doi: 10.1016/S1470-2045(23)00292-9. Corrected and republished in: Lancet Oncol. 2023 Dec;24(12):e461-e471. doi: 10.1016/S1470-2045(23)00334-0. PMID: 35940183 Retracted. Retracted and republished. Corrected and republished. Clinical Trial.
-
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.Expert Rev Anticancer Ther. 2022 Jan;22(1):17-25. doi: 10.1080/14737140.2022.2017286. Epub 2022 Jan 2. Expert Rev Anticancer Ther. 2022. PMID: 34904502 Review.
-
Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.Drugs. 2016 Apr;76(5):605-15. doi: 10.1007/s40265-016-0562-7. Drugs. 2016. PMID: 26984388 Review.
Cited by
-
Multiple Options: How to Choose Therapy in Frontline Metastatic Melanoma.Curr Oncol Rep. 2024 Jun 5. doi: 10.1007/s11912-024-01547-0. Online ahead of print. Curr Oncol Rep. 2024. PMID: 38837107 Review.
-
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.Signal Transduct Target Ther. 2024 May 22;9(1):126. doi: 10.1038/s41392-024-01826-z. Signal Transduct Target Ther. 2024. PMID: 38773064 Free PMC article. Review.
-
Anorectal mucosal melanoma.Semin Colon Rectal Surg. 2023 Dec;34(4):100990. doi: 10.1016/j.scrs.2023.100990. Epub 2023 Oct 17. Semin Colon Rectal Surg. 2023. PMID: 38746826
-
RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.Int J Mol Sci. 2024 Apr 24;25(9):4633. doi: 10.3390/ijms25094633. Int J Mol Sci. 2024. PMID: 38731852 Free PMC article. Review.
-
Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance.Cancers (Basel). 2024 Apr 19;16(8):1571. doi: 10.3390/cancers16081571. Cancers (Basel). 2024. PMID: 38672652 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous